比美吉珠单抗治疗严重掌跖脓疱型银屑病
这项病例系列纳入21例掌跖脓疱病或伴脓疱的掌跖斑块状银屑病成人患者,在法国7家三级皮肤科中心接受比美吉珠单抗治疗至少3个月。17例在1至4个月内达到IGA 0分完全清除,3例达IGA 1分,1例达IGA 2分;4例念珠菌感染经口服抗真菌药治愈,无人因不良事件停药。
要点
- 比美吉珠单抗可使多数掌跖脓疱病患者在1至4个月内达到完全清除。
- 3例合并Hallopeau连续性肢端皮炎者甲受累改善50%至70%。
- 2例SAPHO综合征患者皮损完全清除且关节痛改善。
核心结论
- 比美吉珠单抗可能对掌跖脓疱病、伴脓疱的掌跖斑块状银屑病及SAPHO综合征是一种有吸引力的治疗选择。
研究设计与样本
- 病例系列纳入21例成人患者,其中掌跖脓疱病11例、伴脓疱的掌跖斑块状银屑病10例。
- 患者来自法国7家三级皮肤科中心,治疗时间为2022年9月至2023年6月。
- 分析纳入所有接受比美吉珠单抗治疗至少3个月的患者。
主要发现
- 17例在1至4个月内达到IGA 0分完全清除,3例达IGA 1分,1例达IGA 2分。
- 3例合并Hallopeau连续性肢端皮炎者甲受累在治疗4至6个月后改善50%至70%。
- 2例SAPHO综合征患者皮损完全清除且关节痛改善。
- 4例(19%)念珠菌感染经口服抗真菌药成功治疗,无人因不良事件停用比美吉珠单抗。
临床怎么用
- 对传统系统治疗反应不佳的掌跖脓疱病或伴脓疱的掌跖斑块状银屑病患者,可考虑比美吉珠单抗。
- 治疗期间需关注念珠菌感染,本系列中口服抗真菌药可有效处理。
局限性
- 本研究为病例系列,样本量有限,需前瞻性随机安慰剂对照临床试验确认这些初步结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Palmoplantar pustulosis (PPP) and palmoplantar plaque psoriasis with pustules remain challenging to treat. Studies suggest that an interleukin 17 or interleukin 36 loop acts synergistically in these diseases to induce palmoplantar pustules. OBJECTIVE: To assess the effectiveness of bimekizumab in treating PPP and palmoplantar plaque psoriasis with pustules. DESIGN, SETTING, AND PARTICIPANTS: This case series involved 21 adults with PPP (11 patients) or palmoplantar plaque psoriasis with pustules (10 patients) treated at 1 of 7 tertiary dermatological centers in France from September 2022 through June 2023. All patients treated with bimekizumab for at least 3 months were included in the analyses. MAIN OUTCOMES AND MEASURES: The main outcome was the posttreatment Investigator Global Assessment (IGA), scored as 0 (complete clearance), 1 (almost clear), 2 (mild), 3 (moderate), or 4 (severe). When relevant, evolution of joint pain and nail involvement was reported. Tolerance and potential adverse events were noted. RESULTS: A total of 21 patients (mean [range] age, 46 [24-68] years; 19 females) were included. Eleven patients had isolated PPP, and 10 had palmoplantar plaque psoriasis with pustules. All of them, except 2 who received bimekizumab as first systemic therapy, had not responded to at least 1 systemic treatment (median [range], 3 [1-7] treatments), and/or had adverse events leading to the discontinuation of the treatment. Complete clearance (IGA score, 0) was achieved by 17 patients in 1 to 4 months. Three patients achieved an IGA score of 1, and 1 achieved an IGA score of 2. Three patients with PPP also presented with acrodermatitis continua of Hallopeau. Nail involvement showed 50% to 70% improvement after 4 to 6 months of bimekizumab treatment for these 3 patients. Two patients had SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome; both had complete clearance of skin lesions associated with joint pain improvement. Four patients (19%) with candidiasis were successfully treated with oral antifungal agents. None of the patients had to stop bimekizumab treatment due to adverse events. CONCLUSIONS AND RELEVANCE: The findings of this case series suggest that bimekizumab could be an appealing approach for treating PPP, palmoplantar plaque psoriasis with pustules, and SAPHO syndrome. Prospective randomized placebo-controlled clinical trials are needed to confirm these encouraging initial results.
引用
- Passeron T, Perrot JL, Jullien D, et al. Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab. JAMA Dermatol. 2024. PMID: 38054800. doi:10.1001/jamadermatol.2023.5051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。